A.N. Chremos

1.0k total citations
26 papers, 821 citations indexed

About

A.N. Chremos is a scholar working on Pharmacology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, A.N. Chremos has authored 26 papers receiving a total of 821 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Pharmacology, 8 papers in Molecular Biology and 6 papers in Pulmonary and Respiratory Medicine. Recurrent topics in A.N. Chremos's work include Asthma and respiratory diseases (6 papers), Lipoproteins and Cardiovascular Health (5 papers) and Respiratory and Cough-Related Research (4 papers). A.N. Chremos is often cited by papers focused on Asthma and respiratory diseases (6 papers), Lipoproteins and Cardiovascular Health (5 papers) and Respiratory and Cough-Related Research (4 papers). A.N. Chremos collaborates with scholars based in United States, Belgium and Canada. A.N. Chremos's co-authors include Reagan H. Bradford, Alexandra Langendörfer, David T. Nash, Charles L. Shear, Frank A. Franklin, Jay A. Cherner, K.E. McArthur, Harold W. Schnaper, John M. Howard and M.J. Cornelius and has published in prestigious journals such as Circulation, Gastroenterology and The American Journal of Medicine.

In The Last Decade

A.N. Chremos

26 papers receiving 770 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
A.N. Chremos United States 18 333 173 126 115 108 26 821
Jack R. Leonards United States 21 243 0.7× 239 1.4× 144 1.1× 68 0.6× 116 1.1× 44 1.1k
Carl‐Eric Elwin Sweden 14 248 0.7× 539 3.1× 313 2.5× 66 0.6× 107 1.0× 26 1.6k
L Sölvell Sweden 15 182 0.5× 75 0.4× 91 0.7× 101 0.9× 67 0.6× 31 655
Eva Bredberg Sweden 17 444 1.3× 73 0.4× 115 0.9× 321 2.8× 313 2.9× 20 1.1k
Tamara A. Sutfin United States 11 278 0.8× 145 0.8× 95 0.8× 33 0.3× 142 1.3× 13 728
Akinori Urae Japan 17 215 0.6× 173 1.0× 185 1.5× 136 1.2× 494 4.6× 30 1.2k
S. Irie Japan 12 233 0.7× 74 0.4× 88 0.7× 81 0.7× 234 2.2× 17 819
H.‐U. Schulz Germany 15 235 0.7× 119 0.7× 141 1.1× 68 0.6× 239 2.2× 49 912
P.A. Soons Netherlands 16 129 0.4× 152 0.9× 140 1.1× 33 0.3× 261 2.4× 27 876
Hee Youn Choi South Korea 15 568 1.7× 58 0.3× 103 0.8× 110 1.0× 45 0.4× 40 1.0k

Countries citing papers authored by A.N. Chremos

Since Specialization
Citations

This map shows the geographic impact of A.N. Chremos's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by A.N. Chremos with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites A.N. Chremos more than expected).

Fields of papers citing papers by A.N. Chremos

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by A.N. Chremos. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by A.N. Chremos. The network helps show where A.N. Chremos may publish in the future.

Co-authorship network of co-authors of A.N. Chremos

This figure shows the co-authorship network connecting the top 25 collaborators of A.N. Chremos. A scholar is included among the top collaborators of A.N. Chremos based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with A.N. Chremos. A.N. Chremos is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Shear, Charles L., Frank A. Franklin, Sandra S. Stinnett, et al.. (1992). Expanded Clinical Evaluation of Lovastatin (EXCEL) study results. Effect of patient characteristics on lovastatin-induced changes in plasma concentrations of lipids and lipoproteins.. Circulation. 85(4). 1293–1303. 72 indexed citations
3.
Dujovne, Carlos A., A.N. Chremos, James L. Pool, et al.. (1991). Expanded clinical evaluation of lovastatin (EXCEL) study results: IV. Additional perspectives on the tolerability of lovastatin. The American Journal of Medicine. 91(1). S25–S30. 91 indexed citations
4.
Bradford, Reagan H., Charles L. Shear, A.N. Chremos, et al.. (1991). Expanded clinical evaluation of lovastatin (EXCEL) study results: III. Efficacy in modifying lipoproteins and implications for managing patients with moderate hypercholesterolemia. The American Journal of Medicine. 91(1). S18–S24. 34 indexed citations
5.
Lin, J H, et al.. (1988). Effects of age and chronic renal failure on the urinary excretion kinetics of famotidine in man. European Journal of Clinical Pharmacology. 34(1). 41–46. 43 indexed citations
6.
Burget, D. W., et al.. (1987). The effects of intravenous famotidine on pentagastrin‐stimulated gastric secretion in man. Alimentary Pharmacology & Therapeutics. 1(2). 125–132. 5 indexed citations
7.
Halstenson, Charles E., Paul A. Abraham, John A. Opsahl, et al.. (1987). Disposition of Famotidine in Renal Insufficiency. The Journal of Clinical Pharmacology. 27(10). 782–787. 23 indexed citations
8.
Yeh, K. C., A.N. Chremos, J H Lin, et al.. (1987). Single‐dose pharmacokinetics and bioavailability of famotidine in man. Results of multicenter collaborative studies. Biopharmaceutics & Drug Disposition. 8(6). 549–560. 38 indexed citations
9.
Chremos, A.N., et al.. (1987). Effects of antacids and food on absorption of famotidine.. British Journal of Clinical Pharmacology. 24(4). 551–553. 23 indexed citations
10.
Chremos, A.N., et al.. (1987). The effect of famotidine on renal function in patients with renal insufficiency.. British Journal of Clinical Pharmacology. 24(3). 385–389. 13 indexed citations
11.
Ryan, Jerome R., et al.. (1987). The effect of various dose regimens of famotidine on basal nocturnal and meal–stimulated gastric secretion. Clinical Pharmacology & Therapeutics. 42(2). 225–231. 12 indexed citations
12.
Chremos, A.N.. (1987). Clinical Pharmacology of Famotidine: A Summary. Journal of Clinical Gastroenterology. 9(Supplement 2). 7–12. 23 indexed citations
13.
Chremos, A.N., et al.. (1987). Comparative effect of famotidine and cimetidine on the pharmacokinetics of theophylline in normal volunteers.. British Journal of Clinical Pharmacology. 24(5). 669–672. 19 indexed citations
14.
Chremos, A.N.. (1986). Pharmacodynamics of famotidine in humans. The American Journal of Medicine. 81(4). 3–7. 24 indexed citations
15.
Skoutakis, Vasilios A., et al.. (1985). The Comparative Bioavailability of Liquid, Wax‐Matrix, and Microencapsulated Preparations of Potassium Chloride. The Journal of Clinical Pharmacology. 25(8). 619–621. 5 indexed citations
16.
McCallum, Richard W., et al.. (1985). MK-208, a novel histamine H2-receptor inhibitor with prolonged antisecretory effect. Digestive Diseases and Sciences. 30(12). 1139–1144. 26 indexed citations
17.
Howard, John M., A.N. Chremos, Martin J. Collen, et al.. (1985). Famotidine, a New, Potent, Long-Acting Histamine H2-Receptor Antagonist: Comparison With Cimetidine and Ranitidine in the Treatment of Zollinger-Ellison Syndrome. Gastroenterology. 88(4). 1026–1033. 154 indexed citations
18.
Sedor, John R., et al.. (1984). Effects of sulindac and indomethacin on renal prostaglandin synthesis. Clinical Pharmacology & Therapeutics. 36(1). 85–91. 54 indexed citations
19.
Zambraski, Edward J., et al.. (1984). Comparison of the effects of sulindac with other cyclooxygenase inhibitors on prostaglandin excretion and renal function in normal and chronic bile duct-ligated dogs and swine.. Journal of Pharmacology and Experimental Therapeutics. 228(3). 560–566. 22 indexed citations
20.
Turnbull, Lennox B., et al.. (1976). Disposition of bethanidine, N-benzyl-N',N''-dimethylguanidine, in the rat, dog and man.. Drug Metabolism and Disposition. 4(3). 269–275. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jack R. Leonards Breakdown of academic impact, for papers by Carl‐Eric Elwin Breakdown of academic impact, for papers by L Sölvell Breakdown of academic impact, for papers by Eva Bredberg Breakdown of academic impact, for papers by Tamara A. Sutfin Breakdown of academic impact, for papers by Akinori Urae Breakdown of academic impact, for papers by S. Irie Breakdown of academic impact, for papers by H.‐U. Schulz Breakdown of academic impact, for papers by P.A. Soons Breakdown of academic impact, for papers by Hee Youn Choi
Rankless by CCL
2026